...
首页> 外文期刊>Journal of Gastroenterology >Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan
【24h】

Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan

机译:自身免疫性胰腺炎的治疗方法:日本对自身免疫性胰腺炎的治疗方法达成共识

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Autoimmune pancreatitis (AIP) has been characterized by unique clinical imaging, immunological findings, and the effectiveness of steroid therapy. A set of clinicopathological criteria for AIP was proposed by the Japan Pancreatic Society in 2002, and AIP has come to be widely recognized among general digestive clinicians. However, the indication of steroid therapy for AIP is still not well established, and furthermore the therapeutic doses and method of administration of steroid therapy is also unclear. Recently, an epidemiological survey of all the treatments used for AIP in Japan was conducted by the Research Committee of Intractable Pancreatic Diseases, and their report “Consensus for a Treatment of Autoimmune Pancreatitis” was produced. In a comparison of the results of steroid therapy and nonsteroid therapy for AIP in relation to the rate of complete remission, the recurrence rate, and the period needed to guarantee complete remission, it was thought that the administration of a steroid should be a standard therapy for AIP. However, if the diagnosis of AIP is still uncertain, steroid therapy should be given with caution. In addition, even when AIP still appears to be possible after a course of steroid therapy, a re-evaluation should be carried out taking pancreatic carcinoma into consideration. An initial steroid dose of 30–40 mg per day is recommended. With continuous and careful observations of the clinical manifestations, laboratory data, and imaging findings after administration of the initial dose of steroid for 2–4 weeks, the quantity of steroid can be reduced gradually to a maintenance dose in 2–3 months, and then reduced to 2.5–5 mg per day after remission. The recommended period of maintenance treatment is still unclear, but the administration of the steroid could be stopped after a period of about 6–12 months of treatment, although the patient should be monitored for clinical manifestations of improvement. In addition, the patient's progress should be followed taking recurrence into consideration. In order to evaluate the effectiveness of steroid therapy, follow-up observations should include biochemical examinations of blood findings such as serum γ-globulin, IgG, and IgG 4, imaging findings, and clinical manifestations such as jaundice and abdominal discomfort.
机译:自身免疫性胰腺炎(AIP)的特征在于独特的临床影像学,免疫学发现和类固醇治疗的有效性。日本胰腺学会于2002年提出了一套AIP的临床病理学标准,AIP已在一般消化临床医生中得到广泛认可。然而,仍未充分确定用于AIP的类固醇疗法的适应症,并且还不清楚类固醇疗法的治疗剂量和给药方法。最近,难治性胰腺疾病研究委员会对日本用于AIP的所有治疗方法进行了流行病学调查,并编制了报告“治疗自身免疫性胰腺炎的共识”。在比较AIP的类固醇治疗和非类固醇治疗的结果与完全缓解率,复发率和保证完全缓解所需的时间之间的比较时,认为类固醇的给药应为标准治疗用于AIP。但是,如果仍不确定AIP的诊断,应谨慎使用类固醇治疗。此外,即使经过类固醇治疗后仍可能出现AIP,也应考虑胰腺癌进行重新评估。建议初始类固醇剂量为每天30–40 mg。在连续服用最初的类固醇2至4周后,通过对临床表现,实验室数据和影像学表现的连续和仔细观察,类固醇的量可在2-3个月内逐渐减少至维持剂量,然后缓解后每天减少至2.5-5 mg。推荐维持治疗的时间尚不清楚,但是在治疗约6-12个月后可停止类固醇的给药,尽管应监测患者的临床改善情况。另外,应考虑患者的病情进展并考虑复发情况。为了评估类固醇治疗的有效性,后续观察应包括对血液检查结果(如血清γ-球蛋白,IgG和IgG 4)的生化检查,影像学检查结果以及黄疸和腹部不适等临床表现。

著录项

  • 来源
    《Journal of Gastroenterology》 |2007年第s18期|50-58|共9页
  • 作者单位

    Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences Kyushu University 3-1-1 Maidashi Higashi-ku Fukuoka 812-8582 Japan;

    Department of Gastroenterology and Hepatology Kochi Medical School Kochi Japan;

    Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences Kyushu University 3-1-1 Maidashi Higashi-ku Fukuoka 812-8582 Japan;

    Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences Kyushu University 3-1-1 Maidashi Higashi-ku Fukuoka 812-8582 Japan;

    Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences Kyushu University 3-1-1 Maidashi Higashi-ku Fukuoka 812-8582 Japan;

    Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences Kyushu University 3-1-1 Maidashi Higashi-ku Fukuoka 812-8582 Japan;

    Third Department of Internal Medicine Kansai Medical University Kansai Japan;

    Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences Kyushu University 3-1-1 Maidashi Higashi-ku Fukuoka 812-8582 Japan;

    Department of Gastroenterology and Metabolism University of Occupational and Environmental Health Japan School of Medicine Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    autoimmune pancreatitis; steroid; therapy; survey;

    机译:自身免疫性胰腺炎;类固醇;治疗;调查;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号